Thermal Cures in the Treatment of Multiple Sclerosis

Thermal Cures in the Treatment of Multiple Sclerosis: Effectiveness on the Quality of Life

Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.

Multiple sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, and its consequences in terms of public health are important. In this disease, the alteration of the quality of life (QoL) is constant and multifactorial : pain, fatigue, decrease in functional capacities, sleep disorders, cognitive disorders, vesico-sphincterian disorders, anomolytic disorders. -rectal and genito-sexual. The benefit of thermal cures on the quality of life in this population has not been evaluated, even if there is some literature in the literature suggesting a benefit of hydrotherapy on equilibrium or on pain.

Inclusion Criteria:

• Patient with primary or progressive secondary-phase MS
• Showing EDSS <7 severity criteria
• Patient with MS for whom an indication of spa treatment has been made,
• Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure",
• Patient receiving the general social security scheme,
• Patient having given written consent to participate in the study

Exclusion Criteria:

• Patient does not meet the inclusion criteria,
• Patient with relapsing remitting MS
• Patient unfit according to the investigator to complete the rating scales
• Patient with heat intolerance called "Uhthoff effect"
• Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease.
• Patient with serious life-threatening condition (ie, cancer)
• Patient under tutorship or curatorship
• Patient participating in another interventional clinical research project